BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 17895400)

  • 1. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease.
    Imbimbo BP; Giardino L; Sivilia S; Giuliani A; Gusciglio M; Pietrini V; Del Giudice E; D'Arrigo A; Leon A; Villetti G; Calzà L
    J Alzheimers Dis; 2010; 20(1):159-73. PubMed ID: 20164581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
    Imbimbo BP; Hutter-Paier B; Villetti G; Facchinetti F; Cenacchi V; Volta R; Lanzillotta A; Pizzi M; Windisch M
    Br J Pharmacol; 2009 Mar; 156(6):982-93. PubMed ID: 19239474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.
    Imbimbo BP; Del Giudice E; Cenacchi V; Volta R; Villetti G; Facchinetti F; Riccardi B; Puccini P; Moretto N; Grassi F; Ottonello S; Leon A
    Pharmacol Res; 2007 Apr; 55(4):318-28. PubMed ID: 17292621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice.
    Balducci C; Mehdawy B; Mare L; Giuliani A; Lorenzini L; Sivilia S; Giardino L; Calzà L; Lanzillotta A; Sarnico I; Pizzi M; Usiello A; Viscomi AR; Ottonello S; Villetti G; Imbimbo BP; Nisticò G; Forloni G; Nisticò R
    J Alzheimers Dis; 2011; 24(4):799-816. PubMed ID: 21321397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.
    Porrini V; Lanzillotta A; Branca C; Benarese M; Parrella E; Lorenzini L; Calzà L; Flaibani R; Spano PF; Imbimbo BP; Pizzi M
    Neuroscience; 2015 Aug; 302():112-20. PubMed ID: 25450955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.
    Sivilia S; Lorenzini L; Giuliani A; Gusciglio M; Fernandez M; Baldassarro VA; Mangano C; Ferraro L; Pietrini V; Baroc MF; Viscomi AR; Ottonello S; Villetti G; Imbimbo BP; Calzà L; Giardino L
    BMC Neurosci; 2013 Apr; 14():44. PubMed ID: 23560952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
    Rakover I; Arbel M; Solomon B
    Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-dependent differential expression of BACE splice variants in brain regions of tg2576 mice.
    Zohar O; Pick CG; Cavallaro S; Chapman J; Katzav A; Milman A; Alkon DL
    Neurobiol Aging; 2005; 26(8):1167-75. PubMed ID: 15917100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
    Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
    J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice.
    Goldstein ME; Cao Y; Fiedler T; Toyn J; Iben L; Barten DM; Pierdomenico M; Corsa J; Prasad CV; Olson RE; Li YW; Zaczek R; Albright CF
    J Pharmacol Exp Ther; 2007 Oct; 323(1):102-8. PubMed ID: 17640949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
    Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
    Stock N; Munoz B; Wrigley JD; Shearman MS; Beher D; Peachey J; Williamson TL; Bain G; Chen W; Jiang X; St-Jacques R; Prasit P
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2219-23. PubMed ID: 16455248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
    Heneka MT; Sastre M; Dumitrescu-Ozimek L; Hanke A; Dewachter I; Kuiperi C; O'Banion K; Klockgether T; Van Leuven F; Landreth GE
    Brain; 2005 Jun; 128(Pt 6):1442-53. PubMed ID: 15817521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
    Wiley JC; Hudson M; Kanning KC; Schecterson LC; Bothwell M
    J Neurochem; 2005 Sep; 94(5):1189-201. PubMed ID: 15992373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
    He J; Luo H; Yan B; Yu Y; Wang H; Wei Z; Zhang Y; Xu H; Tempier A; Li X; Li XM
    Neurobiol Aging; 2009 Aug; 30(8):1205-16. PubMed ID: 18079026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.